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INTRODUCTION
Apoptosis is an active mechanism that leads to cell death.
Tight regulation is essential to ensure a delicate balance bet-
ween life and death, and the loss of apoptosis might proceed
to a wide variety of diseases. Cancer also involves cellular de-
fects that halt apoptosis in its development and progression
of cancer (1). Hence, many studies have demonstrated the
role of different apoptosis regulators in rendering tumor cells
resistant to apoptosis both in vitro and in vivo. The upregu-
lation of anti-apoptotic proteins would certainly assist the
survival of tumor cells (2-5). Various anti-apoptotic proteins
are expressed in different tumors, and their expression may
be related with unfavorable prognostic features at diagnosis
(6-14) and poor treatment responses (14-18).
Over the last decade, a complex network of pro- and anti-
apoptotic proteins that govern the tight regulation of the
apoptosis pathways have been revealed (19-22). Among anti-
apoptotic proteins, a group of proteins, known as the inhibi-
tor of apoptosis protein (IAP), are the only cellular factors
that act both on the initiator and effector caspases (23-26). To
date, eight human IAPs have been identified: NAIP, cIAP1,
cIAP2, XIAP, survivin, apollon, ILP-2, and livin (27). As
their name implies, the IAP family proteins can inhibit the
apoptosis induced by a variety of stimuli. Therefore, the overex-
pression of various IAPs is regarded as an unfavorable factor
in various malignancies. However, in breast cancer, the clin-
ical relevance of IAP overexpression has not been evaluated
with the exception of survivin. The overexpression of sur-
vivin in breast cancer is associated with the presence of unfa-
vorable prognostic factors at diagnosis and a poor clinical
outcome. 
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Neuronal Apoptosis Inhibitory Protein is Overexpressed in Patients
with Unfavorable Prognostic Factors in Breast Cancer
Neuronal apoptosis inhibitory protein (NAIP) is a recently identified inhibitor of apop-
tosis protein. However, the clinical relevance of NAIP expression is not completely
understood. In an attempt to determine the clinical relevance of NAIP expression
in breast cancer, the levels of NAIP and survivin expression were measured in 117
breast cancer samples and 10 normal breast tissues using quantitative reverse-
transcriptase-polymerase chain reaction. While there was no evidence of NAIP
expression in the normal breast tissue, NAIP was expressed in all breast cancer
samples. The level of NAIP expression in breast cancer was significantly higher
(257 times) than in the universal tumor control. There was a strong correlation bet-
ween the level of NAIP expression and the level of survivin expression (p=0.001).
The level of NAIP expression in patients with a large tumor (≥ ≥T2) and patients
with an unfavorable histology (nuclear grade III) was significantly higher than in
those patients with a small tumor (T1) and patients with a favorable histology (nucle-
ar grade I, II) (p=0.026 and p=0.050, respectively). Although the level of NAIP ex-
pression was higher in patients with other unfavorable prognostic factors, it was
not significant. The three-year relapse-free survival rate was not significantly the
patients showing high NAIP expression and patients showing low NAIP expres-
sion (86.47± ±4.79% vs. 78.74± ±6.57%). Further studies should include the expres-
sions of NAIP in a larger number of patients and for a longer period of follow-up to
evaluate correlation with metastasis and treatment outcome. In conclusion, NAIP
is overexpressed in breast cancer patients with unfavorable clinical features such
as stage and tumor size, suggesting that NAIP would play a role in the disease
manifestation. 
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Neuronal apoptosis inhibitory protein (NAIP), which is a
member of the IAPs, is expressed in mammalian cells and
inhibits the apoptosis induced by a variety of signals. This
gene is homologous to two baculovirus IAPs (28). NAIP has
been linked to the inherited disease, spinal muscular atrophy
(SMA), which occurs in children and manifests as a degen-
eration of the motor neurons (29). NAIP may play a role in
the mechanisms of resistance of tumor cells to various chemo-
therapeutic agents. Moreover, the strong expression of IAPs,
particularly Survivin and NAIP, is observed in the bone mar-
row of AMLL (30, 31). However, little is known about the
clinical relevance of NAIP expression in breast cancer.
In this context, this study examined the clinical relevance
of NAIP expression in breast cancer using quantitative reverse
transcriptase-polymerase chain reaction (RT-PCR). The result
showed that overexpression of NAIP was associated with the
unfavorable clinical features of breast cancer. 
MATERIALS AND METHODS
Patients and clinical evaluations
One hundred and seventeen patients, who were newly diag-
nosed as breast cancer at Samsung Medical Center from Au-
gust 2003 to December 2004, were enrolled in this study.
All the patients were diagnosed with a breast carcinoma pre-
operatively by radiological findings and tissue biopsy, and
they did not receive any form of treatment prior to surgery.
All the patients underwent a potentially curative resection,
and the tumor specimens were sent to a pathologist for an
evaluation of various prognostic factors including histologi-
cal subtype, lymph node involvement, expression of estro-
gen receptor (ER), and progesterone receptor (PR). A bone
scan was performed routinely for an evaluation of the stage.
The Institutional Review Board in the Samsung Medical
Center approved this study, and informed consent was ob-
tained from the patients or guardians. 
RNA isolation and cDNA synthesis
The tumor tissue specimens were taken from the periphery
of the tumor mass resected in the operating room and stored
at -70℃ in a RNAlater reagent (Ambion, Austin, U.S.A.).
The tumor tissue specimens were homogenized using a rotor-
stator homogenizer, DIAX 900 (Heidoph, Schwabach, Ger-
many). The total RNA was extracted using a Qiamp kit (Qi-
agen, Chatsworth, U.S.A.) according to the manufacturer’s
protocol. After treatment with DNA-free
� (Ambion) to
remove the chromosomal DNA, the complementary DNA
(cDNA) was synthesized using SuperScript III Reverse Tran-
scriptase (Invitrogen, Carlsbad, U.S.A.) with oligo (dT) 15-
mer primer and stored at -20℃until use.
Quantitative Real-time RT-PCR
The mRNA expression levels of the IAPs and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) were measured
by quantitative RT-PCR using the ABI PRISM 7000 sequ-
ence detector system (Applied Biosystems, Foster City, CA,
U.S.A.). The real-time PCR amplification was carried out
using the pre-developed assay-on-demand gene expression
set for the NAIP gene (Hs00244967_m1, GeneBank acces-
sion number NM_004536, Applied Biosystems), Survivin
gene (Hs00153353_m1, GeneBank accession number NM_
001168, Applied Biosystems), and TaqMan
� GAPDH Con-
trol Reagents (Applied Biosystems) for the GAPDH gene
in combination with the TaqMan
� Universal PCR Master
Mix (Applied Biosystems). 
All the reactions were performed in triplicate using a 20
L sample containing 50 ng of cDNA. The reaction proto-
col involved heating at 50℃ for 2 min and then at 95℃ for
10 min, followed by 40 cycles of amplification cycles (15 sec
at 95℃ and 1 min at 60℃). The analysis was performed
using ABI PRISM 7000 Sequence Detection software (App-
lied Biosystems). The expression level of the IAP genes in
the unknown samples was calculated as the ratios of IAP ver-
sus GAPDH. The IAP and GAPDH mRNA levels were
quantified using a standard curves made from known serial
dilution of Universal Human Reference RNA (Invitrogen,
Carlsbad, U.S.A.). The standard curves were generated by
assuming a linear relationship between the first cycle num-
ber, at which the fluorescence signal increased significantly
(Ct value), and the logarithm of the starting quantity. A ne-
gative control without the template was included in each
experiment. 
Statistical analysis
The differences in the level of IAP expression with respect
to the established clinicopathological prognostic factors and
treatment outcome (occurrence of a relapse) were analyzed
using a Mann-Whitney U test. The Spearman’s rank corre-
lation test was used to assess the gene co-expression patterns
of the NAIP and survivin in breast cancer tissues. The patients
were categorized into two groups according to the NAIP
expression levels (≥median or <median). The relapse-free
survival rates (RFS) in each group were estimated using the
Kaplan-Meier method and compared using the log-rank
test. pvalues <0.05 were considered significant.
RESULTS
Patient characteristics 
One hundred and seventeen patients were enrolled in this
study, and their clinical characteristics are listed in Table 1.Overexpression of NAIP is Associated with Unfavorable Prognostic Factors in Breast Cancer S19
The median age was 59 yr (range 24-76). Thirteen patients
(11.1%) were younger than 35 yr old. Ductal type was the
most common histological subtype (77.8%). The tumor size
was larger than T1 in 91 patients (77.8%). A lymph node
metastasis was present in 57 patients (48.7%). The stage was
higher than IIa in 52 patients (44.4%). The nuclear grade
was III in 74 patients (63.2%) and the histological grade
was III in 58 patients (49.6%). There were 62 (53.0%) and
71 (60.7%) patients with ER- and PR-positive tumors, res-
pectively. 
Expression levels of NAIP were very high in breast cancer 
While there was no evidence of NAIP expression in the
normal breast tissue, NAIP was expressed in all the breast
cancer samples. The level of NAIP expression in breast can-
cer was significantly higher than in universal tumor control.
Fig. 1 shows the relative levels of NAIP and survivin expres-
sion compared with the universal tumor cell control. While
the median levels of survivin expression were 0.8 times that
of the control, the median level of NAIP expression was very
high (257 times that of the control) (Fig. 1A). In addition,
the level of NAIP expression was strongly correlated with
that of survivin (p<0.001, Fig. 1B). 
NAIP expression was associated with the presence of
unfavorable prognostic factors 
Table 1 and Fig. 2 show the level of NAIP expression with
respect to the prognostic factors. The level of NAIP expres-
sion in patients with a large tumor (≥T2), and an unfavor-
able histology (nuclear grade III) was significantly higher
than in the patients with a small tumor (T1) and a favorable
histology (nuclear grade I, II) (p=0.026 and p=0.050, respec-
tively). Although the level of NAIP expression was higher
in patients with the other unfavorable prognostic factors (age
<35 yr, positive node involvement, ≥IIb stage, and nega-
tive PR expression), it was not significant. 
In most cases, survivin overexpression was associated with
the presence of unfavorable prognostic factors. However, for
the lymph node metastasis, and stage, the level of survivin
overexpression was higher in early staged disease than in
advanced disease (p=0.030 and 0.057, respectively). 
NAIP
Median p value
No. (%)
Survivin
Median p value
Age
≥35 104 (88.9) 216.0 0.805
<35 13 (11.1) 324.0 0.485 2.621 0.004*
Tumor size
T1 26 (22.2) 102.0 0.704
T2-4 91 (77.8) 319.0 0.026* 0.890 0.657
Node involvement
Negative 60 (51.3) 202.0 1.084
Positive 57 (48.7) 264.5 0.604 0.654 0.030*
Stage
≤IIa 64 (54.7) 190.5 0.974
≥IIb 52 (44.4) 287.0 0.532 0.654 0.057
Nuclear grade
I, II 40 (34.2) 198.5 0.381
III 74 (63.2) 306.0 0.050 0.975 0.033*
Histologic grade
I, II 43 (36.7) 324.0 0.574
III 58 (49.6) 221.0 0.768 1.225 0.003*
ER expression
Positive 55 (47.0) 257.0 0.735
Negative 62 (53.0) 244.5 0.692 1.060 0.026*
PR expression
Positive 46 (39.3) 211.5 0.805
Negative 71 (60.7) 314.0 0.253 0.944 0.234
Table 1. Relationship between levels of NAIP and survivin ex-
pression and the clinicopathological prognostic factors at diag-
nosis
Differences in expression of NAIP and survivin according to established
clinicopathological prognostic factors were analyzed using a Mann-Whi-
tney U test. The expression levels are presented as median values. p
values of <0.05 were considered significant.
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Fig. 1. Relative expression levels of NAIP and survivin mRNA compared with universal human reference RNA. The level of NAIP expres-
sion was 257 times higher than the control, whereas the median level of survivin expression was 0.8 times that of the control (A). The cor-
relations between NAIP and survivin expression in each patient were analyzed by a Spearman’s rank correlation test. Positive correlation
was observed between NAIP and survivin (B, p=0.0001).
NAIP Survivin
p<0.0001
A
S
u
r
v
i
v
i
n
1,000
100
10
1
0.1
0.01
B
1,000,000
100,000
10,000
1,000 100 10 1
NAIP
NAIP vs. Survivin
p value=0.0001S20 J. Choi, Y.K. Hwang, Y.J. Choi, et al.
NAIP expression was high in the patients with a poorer
treatment outcome 
The median follow-up duration was 28 months (range, 1-
75). The tumor relapsed in 16 patients, and treatment-relat-
ed mortality occurred in 6 patients. The 3-yr overall survival
(OS) and RFS rates (±SE) were 82.2±7.0% and 76.0±
6.8%, respectively. 
Higher levels of NAIP expression were found to be asso-
ciated with a less favorable treatment outcome, but this was
not significant. The median levels of NAIP expression in
the relapsed patients (n=16) and relapse-free patients (n=
84) were 266 and 202, respectively (p=0.608, Fig. 3A). Sim-
ilarly, the 3-yr RFS rate was lower in the patients showing
NAIP overexpression (≥median) than in those not show-
ing NAIP overexpression (78.74±6.57% vs. 86.47±4.79
%, p=0.511, Fig. 3B). Survivin overexpression was not asso-
ciated with an unfavorable treatment outcome in this study
(data not shown).
DISCUSSION
While the expression of various IAPs and their prognos-
tic significance has been examined in different cancers (6-
18), survivin is the only IAP that has been evaluated for its
expression and clinical relevance in breast cancer to date (32-
35). To the best of our knowledge, there are no reports of
the expression of the other IAPs other than survivin in breast
cancer tissues. This study is the first to evaluate the level of
NAIP expression in breast cancer using quantitative RT-PCR
in an attempt to determine a possible association with the
established clinicopathological prognostic factors. 
While NAIP was not expressed in the normal breast tis-
sue but was expressed at high levels in breast cancer com-
pared with the universal tumor control. This suggests that
quantitative RT-PCR for NAIP can be used to find a mini-
mal tumor in the regional lymph node or bone marrow.
Because RT-PCR is more sensitive than either immunohis-
tochemistry or a conventional pathologic examination, quan-
titative RT-PCR for NAIP might be valuable in detecting
minimal disease if NAIP expression is still not detected in
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Fig. 3. Expression of NAIP was slightly higher in relapsed patients than in relapse-free patients (266 vs. 202 folds of control, p=0.608). (A)
The relapse-free survival rate also was slightly higher in patients with a high level of NAIP expression (86.47±4.79%) than in patients with
a low level of NAIP expression (78.74±6.57%) (B). This three-year relapse-free survival according to NAIP expression did not show a
statistical significance (p=0.511). 
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Fig. 2. Levels of NAIP expression according to clinicopathologic prognostic factors. NAIP overexpression was correlated with the presence
of unfavorable prognostic factors, T2 (A) and nuclear grade III (B). 
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Bthe further experiment on a large number of normal breast,
lymph node and bone marrow tissues. 
Expression of survivin and other IAPs can be measured by
immunohistochemistry (IHC) using antibodies, conventional
RT-PCR, and quantitative RT-PCR. Although IHC appear
to be a more specific method for detecting biologically and
clinically significant cancer micrometastases in histological-
ly normal specimen in some cancers, RT-PCR appears to be
a more sensitive method maintaining a reasonable specifici-
ty (36-39). The IHC method has some advantages in detect-
ing specific antigen protein including histological observa-
tions while RT-PCR guarantees high sensitivity and quanti-
tative analysis in a total amount of RNA specimen. Howev-
er, RNA expression itself does not reflect the protein expres-
sion exactly. Therefore, complementary use of two methods
is recommended. 
While survivin overexpression is known to be strongly asso-
ciated with the unfavorable clinical features and RFS rate in
breast cancer (32-34), survivin overexpression was not signif-
icantly correlated with RFS rate in this study. The NAIP ex-
pression level was strongly correlated with survivin overex-
pression, however, poorer treatment outcomes were not sig-
nificantly correlated with NAIP overexpression. We assume
that a small number of patients and a relatively short follow-
up duration might have resulted in an insignificant correla-
tion between NAIP expressions and clinical outcome. 
Interestingly, survivin expression was inversely correlated
with the disease extent (lymph node metastasis and stage),
while NAIP expression was not significantly associated with
the disease extent. These results are partly similar with those
reported by Span et al. (33) in that overexpression of survivin
was correlated with unfavorable prognostic factors (young
age, unfavorable histologic grade, and negative ER expres-
sion). However, unlike those studies, our study showed that
overexpression of survivin was correlated with negative node
involvement and less advanced stage. Three splicing variants
of survivin mRNA were detected in breast cancer tissue, and
levels of both survivin-2B and survivin-DeltaEx3 but not
survivin were significantly higher in nodal metastasiss than
primary carcinomas (40). Similarly the overexpression of
other IAPs showed strong correlations with negative lymph
node metastasis and less advanced stage in our study (data
not shown).
The IAP family proteins inhibit apoptosis induced by a
variety of stimuli, and therefore, their overexpression is expect-
ed to be associated with the unfavorable clinical features in
a variety of malignancies including AML. However, the clin-
ical significance of IAP overexpression in acute leukemia is
not completely consistent with what was expected from pre-
vious in vitro studies. For example, IAP overexpression was
not always associated with the unfavorable clinical features
in acute leukemia (26). Furthermore, it was recently report-
ed that the high expression of Livin, also a member of IAP
family proteins, is an independent favorable prognostic fac-
tor in childhood ALL (27). This suggests that the role of IAP
in leukemogenesis or in the maintenance of leukemic cells
might be different from what has been previously recognized.
We assume that a complex network of pro- and anti-apop-
totic proteins might have a pivotal role in the controlling
apoptosis pathways and its cellular factors. 
To the best of our knowledge, there have been no reports
on the expression and clinical relevance of IAPs other than
survivin in breast cancer. This study is the first to show an
association between NAIP overexpression and the unfavor-
able clinical features in breast cancer even though there was
no significant association between NAIP overexpression and
an unfavorable treatment outcome. There were a small num-
ber of patients and a relatively short follow-up duration in
this study, which might have confounded the results. There-
fore, a further study on more patients and for a longer follow-
up duration will be needed to elucidate the association bet-
ween NAIP overexpression and the treatment outcome. 
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